Mentioned in ?
References in periodicals archive ?
* Superimposed preeclampsia: CHTN with either the new onset of proteinuria in association with mild hypertension after 20 weeks, or an elevation in blood pressure to severe ranges (systolic BP greater than or equal to 160 mm Hg and/or diastolic BP greater than or equal to 110 mm Hg) despite the use of the maximal dose of one antihypertensive drug.
The patient was discharged on a maximal dose of calcium channel blockers and nitrate.
Thus, we got 18 groups of 7 rats each-9 groups before induction of SIP were as follows: NWN (normal rats on water), ND1N (normal rats on pimozide, minimal dose), N[D.sub.2]N (normal rats on ziprasidone, minimal dose), NWS (normal rats on water), ND1S (normal rats on pimozide, half maximal dose), N[D.sub.2]S (normal rats on ziprasidone, half maximal dose), NWX (normal rats on water), ND1X (normal rats on pimozide, maximal dose), and N[D.sub.2]X (normal rats on ziprasidone, maximal dose).
Due to the limited solubility of fraction NB in the vehicle solution, a dose of 194.5 g/kg was considered as a maximal dose. In order to assess the acute toxicity of fraction NB at this dosage, mice were intragastrically given a bolus dose of 194.5 g/kg of fraction NB.
In Phase 1, patients 10, 11, and 12 each received 10 lumbar and five cervical injections, of 100,000 cells each, which was far below the safe maximal dose.
--There were no safety issues and the cell infusions were well tolerated (with a maximal dose of 246 million cells).
This is equivalent to the lower maximal dose proposed by EMA for adolescents (i.e.
Accordingly, the purpose of this study was to contribute to the understanding of the potential ergogenic effect of inhaled short acting [[beta].sub.2]-agonists at doses up to and including the maximal dose as stipulated on the WADA 2014 Prohibited List (WADA, 2014) on endurance exercise.
Two patients with paraneoplastic polyneuropathy (anti-Hu positive) and one patient with paraprotein mediated polyneuropathy and one with myasthenia gravis discontinued treatment for infectivity (clinical progression or lack of improvement (nonresponders) despite escalation of treatment to maximal dose).
(2) Doses in this study exceed the currently FDA-approved maximal dose of 75 mg daily.

Full browser ?